|
|
TREATMENT XOLIAR
Xolair (Omalizumab) is a monoclonal antibody made by
Genentech / Novartis and used mainly in allergy-related
asthma therapy, with the purpose of reducing allergic
hypersensitivity. Xoliar is a recombinant DNA-derived
humanized IgG1k monoclonal antibody that selectively binds
to human immunoglobulin E (IgE), which is commonly involved
with allergies when present in high amounts in the body.
XOLIAR ONLINE
Due to the lack of information on the long-term
effectiveness and side effects of the drug,
Xolair treatment
is not yet very common, and can be sometimes expensive.
Another barrier to prevalent use is the injectable dosage
form, which requires the patient to visit a physician's
office or clinic every 2 to 4 weeks for undergoing
treatment. Additionally, as IgE could be a natural defense
against parasitic diseases, treatment is not recommended
when living in environments where the presence of parasites
is common. Recent research suggests that IgE might play a
significant role in the immune system's recognition of
cancer cells, so indiscriminate blocking of IgE / receptor
interaction might have unforeseen problems. Clinical studies
have shown that patients who underwent Xolair treatment had
an increased chance of contracting malignancies of various
types, compared with patients who received the placebo drug.
This is considered a statistically significant increase by
the researchers. Concerns have also been raised about
possible induction of nasal polyps, Churg-Strauss syndrome
and adrenal insufficiency.
DOSAGE OF XOLIAR
The dose of Xoliar will be different for different patients.
Your doctor will determine the initial dose of Xoliar.
Xoliar will be received once every 2 or 4 weeks. |
|
